Ambient fine particulate matter inhibits 15-lipoxygenases to promote lung carcinogenesis
Mingyue Li(Tsinghua–Berkeley Shenzhen Institute), George G. Chen(Chinese University of Hong Kong), Haolong Qi(Chinese University of Hong Kong), Zhi Ning(Hong Kong University of Science and Technology), Xiang Long(Peking University Shenzhen Hospital), Wende Li(Lanzhou Jiaotong University), Shucai Yang(Southern Medical University Shenzhen Hospital), Angel W. Y. Kong(Chinese University of Hong Kong), Jing Du(Sichuan University), Nirmal Kumar Gali(Hong Kong University of Science and Technology), Ernest C.W. Chak(Chinese University of Hong Kong), Calvin S.H. Ng(Johnson & Johnson (United States)), Tony Mok(Chinese University of Hong Kong), Yi Liu(Guangdong Medical College), Shanshan Wang(Chinese University of Hong Kong), Lizhong Liu(Shenzhen University), Zhili Zhao(Ministry of Education of the People's Republic of China), Innes Y.P. Wan(Chinese University of Hong Kong), Jia Hao(Chinese University of Hong Kong), Rocky L.K. Ho(Chinese University of Hong Kong), Malcolm J. Underwood(Bristol Royal Infirmary)
Cited by 35
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k